Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9659630 | 0.82 | FFAR4 (0.53) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL9647739 | 0.81 | CA12 (0.61) | CA12CA1CA2CA4CA5A | |
| SCHEMBL9661501 | 0.81 | FFAR4 (0.52) | CA12CA1CA2CA4CA5A | |
| SCHEMBL3148800 | 0.81 | L3MBTL1 (0.56) | CA9POLBMAPTCYP2C9CYP2C19 | |
| SCHEMBL10823263 | 0.81 | ACP1 (0.49) | CA12CA1CA2CA4CA5A | |
| SCHEMBL6541781 | 0.80 | POLB (0.48) | CA12CA1CA2CA5ACA7 | |
| SCHEMBL3145744 | 0.80 | PTPN1 (0.51) | POLBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL6677428 | 0.79 | MTNR1A (0.47) | EGFRPOLBMAPTSMN1; SMN2GAA | |
| SCHEMBL5500930 | 0.78 | PTGER1 (0.43) | CA12CA1CA2CA4CA5A | |
| SCHEMBL27679941 | 0.78 | KDM4E (0.43) | POLBMAPTCYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748995-B1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-1748995-B1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-100540546-C | Be used to regulate 5-HT6 acceptor, 5-HT2A acceptor or both aryl sulfonyl benzos two alkane | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | disclosed |
| CN-1960983-A | Arylsulfonyl benzodioxanes useful for modulation the 5-HT6 receptor, the 5-HT2areceptor or both | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| EP-1748995-A1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | F. Hoffmann-La Roche AG (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105776-A1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | HTR6, HTR7, HTR1F | CA12 4705/4885CA1 3610/4885CA2 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.